Standardised Critical Care Strategies Improve Outcomes Following Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy in an Indian Peritoneal Malignancy Centre

Deepa Chandramohan; Faheez Mohamed; Syam Vikram; Deepak Damodaran; Shafeek Shamsudeen; Faslu Rahman; John J Alapatt; Gokul R Krishnan; R Dayananda; Muhammed P Shahid; Arun P Das; Jinu Varghese; Aditi Bhatt; Dileep Damodaran

doi:10.1007/s13193-023-01803-y

Standardised Critical Care Strategies Improve Outcomes Following Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy in an Indian Peritoneal Malignancy Centre

Indian J Surg Oncol. 2023 Dec;14(4):920-927. doi: 10.1007/s13193-023-01803-y. Epub 2023 Aug 7.

Affiliations

¹ Department of Critical Care, MVR Cancer Centre and Research Institute, Kozhikode, Kerala India.
² Peritoneal Malignancy Institute, Basingstoke and North Hampshire Hospital, Basingstoke, UK.
³ Department of Surgical Oncology, MVR Cancer Centre and Research Institute, Kozhikode, Kerala India.
⁴ Department of Surgical Oncology, KD Hospital, Ahmedabad, Gujarat India.

PMID: 38187832
PMCID: PMC10766987 (available on 2024-12-01)
DOI: 10.1007/s13193-023-01803-y

Abstract

Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) is a major undertaking with profound peri-operative metabolic and haemodynamic alterations. It requires standardised protocols for immediate postoperative intensive care management to improve patient-related outcomes. A retrospective analysis of a prospectively maintained data-base of 244 patients who underwent CRS and HIPEC between June 2017 and July 2022 in our institute was done. Based on the audit, six strategies were implemented, namely, (1) dynamic multiparameter-based IVF therapy to aggressively correct the hyperlactatemia, (2) initiation of IV 20% human albumin infusion from POD-0, (3) correction of serum iCa²⁺ levels, (4) initiation of diuresis from POD-1, (5) prophylactic use of HFNO immediately post-extubation and (6) serum procalcitonin level-based empiric escalation of IV antibiotics. Patients were divided into two cohorts, pre-protocol group of 145 patients (from June 2017 to December 2020) and post-protocol group comprising of 99 patients (from January 2021 to July 2022), and were analysed for compliance and patient-related outcomes. Implementation of these strategies improved the patient-related outcomes among the two cohorts with significant reduction of Clavien-Dindo grade III/IV complications and improvement in failure to rescue (FTR) index (p < 0.05). There was highly significant reduction in median ICU and hospital stay among the two cohorts (p < 0.001). The formulated protocols of management strategies especially multiparameter-based dynamic fluid therapy, planned diuresis and prophylactic HFNO have improved the outcomes in our patients undergoing CRS and HIPEC.

Keywords: Cytoreductive surgery; Hyperthermic intraperitoneal chemotherapy; Morbidity; Outcomes; Postoperative management protocol.

© The Author(s), under exclusive licence to Indian Association of Surgical Oncology 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.